Glycoproteins are an underexploited drug target for cancer
therapeutics.
In this work, we integrated computational methods in network pharmacology
and in silico docking approaches to identify phytochemical
compounds that could potentially interact with several cancer-associated
glycoproteins. We first created a database of phytochemicals from
selected plant species, Manilkara zapota (sapodilla/chico), Mangifera indica (mango), Annona muricata (soursop/guyabano), Artocarpus heterophyllus (jackfruit/langka), Lansium domesticum (langsat/lanzones), and Antidesma
bunius (bignay), and performed pharmacokinetic analysis to
determine their drug-likeness properties. We then constructed a phytochemical–glycoprotein
interaction network and characterized the degree of interactions between
the phytochemical compounds and with cancer-associated glycoproteins
and other glycosylation-related proteins. We found a high degree
of interactions from α-pinene (Mangifera indica), cyanomaclurin (Artocarpus heterophyllus), genistein
(Annona muricata), kaempferol (Annona muricata and Antidesma bunius), norartocarpetin (Artocarpus heterophyllus), quercetin (Annona muricata, Antidesma bunius, Manilkara zapota, Mangifera indica), rutin (Annona muricata, Antidesma bunius, Lansium domesticum), and ellagic acid (Antidesma bunius and Mangifera indica). Subsequent docking analysis confirmed
that these compounds could potentially bind to EGFR, AKT1, KDR, MMP2,
MMP9, ERBB2, IGF1R, MTOR, and HRAS proteins, which are known cancer
biomarkers. In vitro cytotoxicity assays of the plant
extracts showed that the n-hexane, ethyl acetate,
and methanol leaf extracts from A. muricata, L. domesticum and M. indica gave the highest
growth inhibitory activity against A549 lung cancer cells. These may
help further explain the reported cytotoxic activities of select compounds
from these plant species.